FDA: Draft Guidance with Considerations for the Design of Early-Phase Clinical Trials of Cellular and Gene Therapy Products

Due to the increasing interest and activity in the development of CGT products and because of their potential to address unmet medical needs the FDA published this draft guidance. It is intended to facilitate this development by providing recommendations regarding selected aspects of the design of early-phase clinical trials for these products.